🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) clinical trials

Source: the EU Clinical Trials Information System (CTIS) — current trials in our EU (CTIS) register with Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) as lead sponsor. Synced 26 Sep 2026
12Current trials
0Recruiting now
7Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) is the lead sponsor of 12 current clinical trials in our EU (CTIS) register. The drugs named most often in its trials are Aficamten, Capecitabine and Indocyanine Green.

01

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) in the EU trials register (CTIS)

12 trials

Authorised or ongoing trials in the EU Clinical Trials Information System with Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

StudyPhaseStatusCountries
Learning From Early Aficamten In HCM (LEAF-HCM)
2025-523090-42-00 · Cardiovascular Diseases
Drug: Aficamten
Phase 2 Authorised Netherlands
A Phase I Study using Oncolytic AdenoVirus Immunotherapy with Repeat Administrations in Recurrent GliOblastoma (VIRAGO)
2025-524555-31-00 · Nervous System Diseases
Phase 1 Authorised Netherlands
A more sustainable perioperative treatment regimen for gastroesophageal cancer —replacing 5-FU with capecitabine within the FLOT regimen
2026-526209-13-00 · Neoplasms
Phase 1 Authorised Netherlands
Giving Upfront Anti-p40 to Reduce toxicity from Dual Immune Checkpoint Inhibition in MESOthelioma
2026-526036-38-00 · CTIS ↗ · Neoplasms
Phase 2 Authorised Netherlands
A national randomised multi-centre phase II/III trial using MesoPher in ABC borderline resectable pancreatic cancer (PREOPANC-6 trial)
2025-523134-28-00 · CTIS ↗ · Neoplasms
Phase 3 Authorised Netherlands
Accuracy for Imaging Cardiac Sarcoidosis with 68Ga-Pentixafor Positron Emission Tomography/Computed Tomography (68Ga-Pentixafor PET/CT): ASPECT study
2025-523646-27-00 · CTIS ↗ · Diagnosis
Phase 2 Authorised Netherlands
The SURF trial: Optimizing Surgical excision Using Real-time Fluorescence imaging with indocyanine green
2025-523898-42-00 · CTIS ↗ · Neoplasms
Phase 3 Authorised Netherlands
Repurposed Drugs in Research and Cancer Clinical Trials. The ReDiReCCT trial Vemurafenib
2025-523340-12-00 · CTIS ↗ · Neoplasms
Phase 1 Authorised Netherlands
A Phase II single arm open label study of Pembrolizumab and Lenvatinib in patients with high risk locally advanced cervix cancer: an EMBRACE high risk study initiative
2023-506982-73-00 · CTIS ↗ · Female Urogenital Diseases and Pregnancy Complications
Phase 2 Authorised Netherlands
The use of [68Ga]Ga-FAPI PET/MRI in assessing disease activity in patients with Graves’ orbitopathy
2025-521163-12-01 · CTIS ↗ · Immune System Diseases
Phase 1 Authorised Netherlands
Long-term muscle synthetic effects of intradialytic parenteral nutrition in chronic hemodialysis patients
2025-522111-42-02 · CTIS ↗ · Nutritional and Metabolic Diseases
Phase 4 Authorised Netherlands
ENDO-67 project: Investigating ENDOcrine therapy-related questions using Ki67 changes in the window-of-opportunity before breast surgery
2025-521385-10-00 · CTIS ↗ · Neoplasms
Drug: Tamoxifen
Phase 4 Authorised Netherlands
02

Drugs in Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) trials

7 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

By trial register

RegisterTrialsRecruiting
EU register (CTIS)12—

A trial with sites in more than one country appears in each of those registers.

04

Questions about Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) trials

How many clinical trials does Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) sponsor?

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) is the lead sponsor of 12 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Which drugs is Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) testing?

Its current trials name 7 drugs and biologicals as interventions. The most frequent are Aficamten (1), Capecitabine (1), Indocyanine Green (1), Lenvatinib (1) and Pembrolizumab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.